Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) Enterprise Value (2016 - 2025)

Corcept Therapeutics (CORT) has disclosed Enterprise Value for 15 consecutive years, with -$372.2 million as the latest value for Q4 2025.

  • Quarterly Enterprise Value rose 2.92% to -$372.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$372.2 million through Dec 2025, up 2.92% year-over-year, with the annual reading at -$372.2 million for FY2025, 2.92% up from the prior year.
  • Enterprise Value hit -$372.2 million in Q4 2025 for Corcept Therapeutics, up from -$421.7 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$223.5 million in Q4 2021 to a low of -$473.2 million in Q2 2024.
  • Historically, Enterprise Value has averaged -$376.5 million across 5 years, with a median of -$371.1 million in 2022.
  • Biggest five-year swings in Enterprise Value: surged 49.28% in 2021 and later tumbled 93.11% in 2022.
  • Year by year, Enterprise Value stood at -$223.5 million in 2021, then crashed by 93.11% to -$431.7 million in 2022, then grew by 14.7% to -$368.2 million in 2023, then decreased by 4.1% to -$383.3 million in 2024, then grew by 2.92% to -$372.2 million in 2025.
  • Business Quant data shows Enterprise Value for CORT at -$372.2 million in Q4 2025, -$421.7 million in Q3 2025, and -$342.2 million in Q2 2025.